Since the mid-1980s, there has been a resurgence of severe forms of invasive group A streptococcal (GAS) disease in many countries and regions. However, there has not been any systemic epidemiologic analysis of GAS disease reported in mainland China. To analyse the molecular epidemiology of GAS disease, 86 strains from patients in different regions of mainland China were collected. The collection sites included blood, pus, wounds, the epipharynx and other sites. A total of 21 different emm types were identified in the isolates. In both invasive and non-invasive isolates, M1 (29.1 %) and M12 (23.3 %) were the most prevalent types, a different distribution to M type distributions reported in other countries. Furthermore, minor emm gene sequence alterations were noted for six types. Several important GAS virulence factors were detected by PCR using specific primers. The speB and slo genes were detected in all isolates and were species specific. Four superantigen genes, speA, speC, smeZ and ssa, were found in 52 % (45/86), 51 % (44/86), 82 % (71/86) and 23 % (27/86) of isolates, respectively. M1 isolates harboured more speA (84 %) and fewer speC genes (44 %), while M12 isolates had fewer speA (35 %) and more speC genes (100 %). There was also an association between some virulence genes and isolation sites, perhaps due to the correlation between the emm type distribution and virulence gene occurrence. For two important virulence genes related to necrotizing fasciitis, the sil gene was only carried by 11 of 86 isolates, and no sil gene contained the start codon ATA. The sla gene rarely occurred in GAS isolates, only four of 86 GAS strains being positive, including two isolates obtained from blood. In antimicrobial susceptibility tests, the overall rate of drug resistance in GAS isolates was higher than reported rates in other countries, and the resistance rates to erythromycin, tetracycline and clindamycin were 91.8, 93.4 and 80 %, respectively. This epidemiological study may help to understand the pathogenesis of GAS disease and aid in vaccine development.
BanksD. J.,
BeresS. B.,
MusserJ. M.2002; The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence. Trends Microbiol 10:515–521[CrossRef]
BanksD. J.,
LeiB.,
MusserJ. M.2003; Prophage induction and expression of prophage-encoded virulence factors in group A streptococcus serotype M3 strain MGAS315. Infect Immun 71:7079–7086[CrossRef]
Bemer-MelchiorP.,
JuvinM.-E.2000; In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes : influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 44:2999–3002[CrossRef]
BeresS. B. G. L.,
SylvaK. D.,
LeiB. B.2002; Genome sequence of a serotype M3 strain of group A Streptococcus : phage-encoded toxins, the high-virulence phenotype and clone emergence. Proc Natl Acad Sci U S A 99:10078–10083[CrossRef]
BroudyT. B.,
PancholiV.,
FischettiV. A.2001; Induction of lysogenic bacteriophage and phage-associated toxin from group A streptococci during coculture with human pharyngeal cells. Infect Immun 69:1440–1443[CrossRef]
CarapetisJ.,
Robins-BrowneR.,
MartinD.,
Shelby-JamesT.,
HoggG.1995; Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-non-typeable clone. Clin Infect Dis 21:1220–1227[CrossRef]
ChatellierS.,
IhendyaneN.,
KansalR. G.2000; Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and non-severe invasive diseases. Infect Immun 68:3523–3534[CrossRef]
ChiouC.-S.,
LiaoT.-L.,
WangT.-H.,
ChangH.-L.,
LiaoJ.-C.,
LiC.-C.2004; Epidemiology and molecular characterization of Streptococcus pyogenes recovered from scarlet fever patients in Central Taiwan from 1996 to 1999. J Clin Microbiol 42:3998–4006[CrossRef]
DeazavedoJ. C. S.,
YeungR. H.,
BastD. J.,
DuncanC. L.,
BorgiaS. B.,
LowD. E.1999; Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 43:2144–2147
Hidalgo-GrassC.,
RavinsM.,
Dan-GoorM.,
JaffeJ.,
MosesA. E.2002; A locus of group A streptococcus involved in invasive disease and DNA transfer. Mol Microbiol 46:87–99[CrossRef]
Hidalgo-GrassC.,
Dan-GoorM.,
MalyA.2004; Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotizing soft-tissue infections. Lancet 363:696–703[CrossRef]
HoP. L.,
JohnsonD. R.,
YueA. W. Y.,
TsangD. N. C.,
QueT. L.,
BeallB.,
KaplanE. L.2003; Epidemiologic analysis of invasive and noninvasive group A streptococcal isolates in Hong Kong. J Clin Microbiol 41:937–942[CrossRef]
HolmS. E.,
NorrbyA.,
BergholmA. M.,
NorgrenM.1992; Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988–1989. J Infect Dis 166:31–37[CrossRef]
IkebeT.,
WadaA.2002; Dissemination of the phage-associated novel superantigen gene sepL in recent invasive and noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect Immun 70:3227–3233[CrossRef]
KaulR. A.,
McGeerA.,
LowD. E.,
GreenK.,
SchwartzB.,
SimorA. E.1997; Population-based surveillance for group A Streptococcal necrotizing fasciitis, clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 103:18–24[CrossRef]
KiskaD. L.,
ThiedeB.,
CaraccioloJ. & 7 other authors; 1997; Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 176:992–1000[CrossRef]
LouieL.,
SimorA. E.1998; Diagnosis of group A streptococcal necrotizing fasciitis by using PCR to amplify the streptococcal pyrogenic exotoxin B gene. J Clin Microbiol 36:1769–1771
MusserJ. M.,
KupurV.,
SzetoJ.1995; Genetic diversity and relationships among S treptococcus pyogenes strains expressing serotype M1 protein: recent international spread of a subclone causing episodes of invasive disease. Infect Immun 63:994–1003
NagiecM. J.,
LeiB.,
ParkerS. K.,
VasilM. L.2004; Analysis of a novel prophage-encoded group A streptococcus extracellular phospholipase A2
. J Biol Chem 279:45909–45918[CrossRef]
O'BrienK. L.,
BeallB.,
BarrettN. L. & 8 other authors; 2002; Epidemiology of invasive group A streptococcus disease in the United States, 1995–1999. Clin Infect Dis 35:268–276[CrossRef]
SchmitzF.-J.,
BeyerA.,
CharpentierE.2003; Toxin-gene profile heterogeneity among endemic invasive European group A streptococcal isolates. J Infect Dis 188:1578–1586[CrossRef]
VlaminckxB. J. M.,
MasciniE. M.,
SchellekensJ.,
SchoulsL. M.,
PauwA.,
FluitA. C.,
NovakR.,
VerhoefJ.,
SchmitzF. J.2003; Site-specific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J Clin Microbiol 41:4941–4949[CrossRef]
WatanabeY.,
TodomeY.,
OhkuniH.,
SakuradaS.,
IshikawaT.,
YutsudoT.,
FischettiV. A.,
ZabriskieJ. B.2002; Cysteine protease activity and histamine release from the human mast cell line HMC-1 stimulated by recombinant streptococcal pyrogenic exotoxin B/streptococcal cysteine protease. Infect Immun 70:3944–3947[CrossRef]
YuC. E.,
FerrettiJ. J.1991; Molecular characterization of new group A streptococcal bacteriophages containing the gene for streptococcal erythrogenic toxin A ( sepA ). Mol Gen Genet 231:161–168[CrossRef]